Reviews
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
BOC Sciences
Liafensine | BOC Sciences
This active molecular is a SNDR (serotonin-norepinephrine-dopamine reuptake) inhibitor It was originated by Bristol-Myers Squibb for the treatment of major depressive disorder. In Feb 2013, Phase-II clinical trials in Major depressive disorder (treatment-experienced) in Argentina was on going. In May 2013, Bristol-Myers Squibb completed a phase II trial in Argentina, Australia, Austria, Canada, France, India, Italy, Puerto Rico, South Africa, Spain, United Kingdom and USA. In Oct 2013, Bristol-Myers Squibb discontinued a phase II trial in Major depressive disorder (treatment resistant) because of its increased capacity for side effects as well as potential for abuse.
More Scientific Products from BOC Sciences
![Anti-PRAME antibody [EPR20330]](https://d3bkbkx82g74b8.cloudfront.net/eyJidWNrZXQiOiJsYWJyb290cy1pbWFnZXMiLCJrZXkiOiJjb21wYW55X3Byb2R1Y3RfcHJvZmlsZV9pbWFnZV9mMzEwNTY4MGY1NmVmZjU3ZjZhMWRkZTU2M2Q4YjBmODZjMDJkNDE4XzMwMDA3MTg1ODEyLmpwZyIsImVkaXRzIjp7InRvRm9ybWF0IjoianBnIiwicmVzaXplIjp7IndpZHRoIjozMDAsImhlaWdodCI6MzAwLCJmaXQiOiJjb3ZlciIsInBvc2l0aW9uIjoiY2VudGVyIiwiYmFja2dyb3VuZCI6IiNmZmYifSwiZmxhdHRlbiI6eyJiYWNrZ3JvdW5kIjoiI2ZmZiJ9fX0=)
-
OCT 22, 2025CRISPR Virtual Event Series 2025 -
OCT 22, 2025xMAP Connect 2025 Virtual Series
-
OCT 27, 202568th Annual Biosafety and Biosecurity Conference
-
NOV 04, 2025The Simple Way to Protein Research
-
NOV 06, 2025Precision Oncology Showcase
- See More
Opens in a new window
Opens an external site
Opens an external site in a new window